Tirdzniecība Carl Zeiss Meditec AG - AFX CFD
Pievienot izlasei- Kopsavilkums
- Vēsturiskie Dati
- Notikumi
- Peļņas Atskaite
- Bilance
- Naudas Plūsma
- Īpašums
Tirdzniecības Nosacījumi
| Starpība | 0.61 | ||||||||
|
Garās pozīcijas nodeva naktij
Long position overnight fee
Doties uz platformu | -0.024161% | ||||||||
|
Īsās pozīcijas nodeva naktij
Short position overnight fee
Doties uz platformu | -0.020283% | ||||||||
| Nakts laika nodeva | 22:00 (UTC) | ||||||||
| Min. tirgotais daudzums | 1 | ||||||||
| Valūta | EUR | ||||||||
| Drošības rezerve | 20% | ||||||||
| Fondu birža | Germany | ||||||||
| Tirdzniecības komisija | 0% |
*Information provided by Capital.com
Galvenie Statistikas Dati
| Iepriekš. aizvērt* | 132.87 |
| Atvērt* | 135.47 |
| Izmaiņas par 1 gadu* | -1.48% |
| Dienas Diapazons* | 132.37 - 135.47 |
| 52 ned Diapazons | 101.75-154.05 |
| Vidējais apjoms (10 dienas) | 85.67K |
| Vidējais apjoms (3 mēneši) | 1.86M |
| Tirgus Kapitalizācija | 11.93B |
| Cenas/Peļņas Attiecība | 40.68 |
| Izvietotās Akcijas | 89.44M |
| Ieņēmumi | 1.90B |
| EPS | 3.28 |
| Dividende (Ienesīgums %) | 0.8249 |
| Beta | 0.66 |
| Nākamās Peļņas Datums | Feb 10, 2023 |
"Visus datus nodrošina Refinitiv, izņemot datus, kas atzīmēti ar zvaigznīti, kas ir *dati, kurus nodrošina Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Aizvēršana | Change | Change (%) | Atvēršana | High | Low |
|---|---|---|---|---|---|---|
| Feb 7, 2023 | 132.87 | -4.44 | -3.23% | 137.31 | 137.66 | 132.37 |
| Feb 6, 2023 | 137.17 | -0.74 | -0.54% | 137.91 | 140.71 | 136.67 |
| Feb 3, 2023 | 141.61 | 2.65 | 1.91% | 138.96 | 142.51 | 137.51 |
| Feb 2, 2023 | 140.01 | 6.54 | 4.90% | 133.47 | 140.21 | 133.47 |
| Feb 1, 2023 | 131.57 | 0.00 | 0.00% | 131.57 | 133.31 | 131.02 |
| Jan 31, 2023 | 131.42 | 0.59 | 0.45% | 130.83 | 132.52 | 130.03 |
| Jan 30, 2023 | 132.67 | 1.35 | 1.03% | 131.32 | 132.77 | 130.28 |
| Jan 27, 2023 | 132.57 | 1.20 | 0.91% | 131.37 | 132.77 | 130.28 |
| Jan 26, 2023 | 131.37 | 0.30 | 0.23% | 131.07 | 133.12 | 131.07 |
| Jan 25, 2023 | 129.58 | -0.80 | -0.61% | 130.38 | 131.07 | 127.38 |
| Jan 24, 2023 | 131.67 | -1.50 | -1.13% | 133.17 | 133.82 | 130.73 |
| Jan 23, 2023 | 133.12 | 0.35 | 0.26% | 132.77 | 134.22 | 129.93 |
| Jan 20, 2023 | 132.07 | 1.15 | 0.88% | 130.92 | 132.62 | 130.78 |
| Jan 19, 2023 | 130.93 | -3.49 | -2.60% | 134.42 | 135.87 | 130.93 |
| Jan 18, 2023 | 135.52 | -1.00 | -0.73% | 136.52 | 137.26 | 135.32 |
| Jan 17, 2023 | 134.77 | -0.75 | -0.55% | 135.52 | 135.92 | 133.32 |
| Jan 16, 2023 | 136.42 | 2.50 | 1.87% | 133.92 | 137.36 | 133.87 |
| Jan 13, 2023 | 134.32 | 4.39 | 3.38% | 129.93 | 134.42 | 129.78 |
| Jan 12, 2023 | 130.58 | 1.00 | 0.77% | 129.58 | 131.72 | 128.63 |
| Jan 11, 2023 | 131.92 | 4.14 | 3.24% | 127.78 | 132.71 | 127.48 |
Carl Zeiss Meditec AG Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Ikgadējs
- Ceturkšņa
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Kopējie ienākumi | 1088.36 | 1189.9 | 1280.86 | 1459.32 | 1335.45 | 1646.79 |
| Ienākumi | 1088.36 | 1189.9 | 1280.86 | 1459.32 | 1335.45 | 1646.79 |
| Cost of Revenue, Total | 508.819 | 533.163 | 570.471 | 627.437 | 589.935 | 679.572 |
| Bruto Peļņa | 579.546 | 656.733 | 710.389 | 831.884 | 745.517 | 967.213 |
| Kopējie Darbības Izdevumi | 934.033 | 1009.07 | 1083.73 | 1194.66 | 1157.9 | 1273.17 |
| Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 301.808 | 337.647 | 353.646 | 393.913 | 349.161 | 363.98 |
| Pētniecība un Attīstība | 123.406 | 145.792 | 159.628 | 173.312 | 218.804 | 232.066 |
| Darbības Izdevumi | 154.332 | 180.83 | 197.13 | 264.659 | 177.552 | 373.614 |
| Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | -11.225 | 8.29 | -20.449 | -34.497 | -21.351 | -32.12 |
| Citi, Neto | -1.146 | -0.564 | 2.502 | -0.304 | 22.516 | -2.444 |
| Neto Ienākumi Pirms Nodokļu Nomaksas | 141.961 | 188.556 | 179.183 | 229.858 | 178.717 | 339.05 |
| Neto Ienākumi Pēc Nodokļu Nomaksas | 99.97 | 135.778 | 126.23 | 160.579 | 123.421 | 237.519 |
| Mazākuma Interese | -1.64 | -1.333 | 0.233 | -0.823 | -1.036 | -1.243 |
| Neto Ienākumi Pirms Ārkārtas Posteņiem | 98.33 | 134.445 | 126.463 | 159.756 | 122.385 | 236.276 |
| Neto Ienākumi | 98.33 | 134.445 | 126.463 | 159.756 | 122.385 | 236.276 |
| Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | 98.33 | 134.445 | 126.463 | 159.756 | 122.385 | 236.276 |
| Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | 98.33 | 134.445 | 126.463 | 159.756 | 122.385 | 236.276 |
| Atšķaidītie Neto Ienākumi | 98.33 | 134.445 | 126.463 | 159.756 | 122.385 | 236.276 |
| Atšķaidītie Ienākumi par Akcijām | 81.3096 | 85.5867 | 89.4406 | 89.4406 | 89.4406 | 89.4406 |
| Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | 1.20933 | 1.57086 | 1.41393 | 1.78617 | 1.36834 | 2.64171 |
| Dividends per Share - Common Stock Primary Issue | 0.42 | 0.55 | 0.55 | 0.65 | 0.5 | 0.9 |
| Atšķaidītā Normalizētā Peļņa par Akciju | 1.20933 | 1.46924 | 1.44229 | 1.826 | 1.41621 | 2.62254 |
| Neparedzēti Izdevumi (Ienākumi) | -7.478 | 0 | -2.447 | |||
| Other Operating Expenses, Total | -0.058 | -0.015 | 0 |
| Q2 2021 | Q3 2021 | Q4 2021 | Q1 2021 | Q2 2022 | |
|---|---|---|---|---|---|
| Kopējie ienākumi | 398.456 | 430.834 | 448.585 | 410.176 | 445.229 |
| Ienākumi | 398.456 | 430.834 | 448.585 | 410.176 | 445.229 |
| Cost of Revenue, Total | 167.701 | 169.459 | 180.772 | 177.401 | 176.654 |
| Bruto Peļņa | 230.755 | 261.375 | 267.813 | 232.775 | 268.575 |
| Kopējie Darbības Izdevumi | 309.186 | 310.724 | 357.771 | 335.808 | 342.273 |
| Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 84.081 | 86.291 | 111.48 | 97.871 | 95.837 |
| Pētniecība un Attīstība | 57.404 | 54.927 | 65.566 | 60.536 | 69.692 |
| Neparedzēti Izdevumi (Ienākumi) | 0 | 0.047 | -0.047 | 0 | 0.09 |
| Darbības Izdevumi | 89.27 | 120.11 | 90.814 | 74.368 | 102.956 |
| Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | -9.995 | -3.625 | -11.82 | -20.181 | -8.662 |
| Citi, Neto | -0.181 | -0.217 | -1.944 | -0.115 | 25.805 |
| Neto Ienākumi Pirms Nodokļu Nomaksas | 79.094 | 116.268 | 77.05 | 54.072 | 120.099 |
| Neto Ienākumi Pēc Nodokļu Nomaksas | 55.173 | 81.199 | 54.819 | 38.009 | 92.095 |
| Mazākuma Interese | -0.864 | 0.389 | -0.743 | -0.069 | -1.367 |
| Neto Ienākumi Pirms Ārkārtas Posteņiem | 54.309 | 81.588 | 54.076 | 37.94 | 90.728 |
| Neto Ienākumi | 54.309 | 81.588 | 54.076 | 37.94 | 90.728 |
| Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | 54.309 | 81.588 | 54.076 | 37.94 | 90.728 |
| Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | 54.309 | 81.588 | 54.076 | 37.94 | 90.728 |
| Atšķaidītie Neto Ienākumi | 54.309 | 81.588 | 54.076 | 37.94 | 90.728 |
| Atšķaidītie Ienākumi par Akcijām | 89.0312 | 88.6826 | 89.8211 | 89.5912 | 89.8297 |
| Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | 0.61 | 0.92 | 0.60204 | 0.42348 | 1.01 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0.9 | 0 | 0 |
| Atšķaidītā Normalizētā Peļņa par Akciju | 0.61 | 0.92037 | 0.60167 | 0.42348 | 1.01077 |
- Ikgadējs
- Ceturkšņa
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Apgrozāmo Līdzekļu Kopsumma | 857.463 | 1207.89 | 1251.06 | 1304.33 | 1290.51 | 1604.02 |
| Nauda un Īstermiņa Ieguldījumi | 8.71 | 8.315 | 7.843 | 22.639 | 6.202 | 7.439 |
| Cash | 8.71 | 3.925 | 6.678 | 22.639 | 6.202 | 7.439 |
| Nauda un Ekvivalenti | 0 | |||||
| Debitoru Parādu Kopsumma, Neto | 627.012 | 935.904 | 981.046 | 1000.34 | 979.93 | 1294.65 |
| Accounts Receivable - Trade, Net | 189.244 | 195.256 | 192.33 | 205.789 | 165.158 | 185.94 |
| Total Inventory | 208.309 | 234.303 | 248.092 | 268.322 | 286.36 | 286.375 |
| Prepaid Expenses | 9.962 | 9.986 | 9.352 | 10.759 | 8.144 | 9.502 |
| Other Current Assets, Total | 3.47 | 19.38 | 4.723 | 2.266 | 9.871 | 6.049 |
| Total Assets | 1247.73 | 1623.11 | 1662.05 | 2022.13 | 2014.85 | 2395.97 |
| Property/Plant/Equipment, Total - Net | 64.509 | 58.696 | 62.632 | 116.752 | 135.265 | 199.555 |
| Property/Plant/Equipment, Total - Gross | 171.048 | 174.346 | 196.305 | 280.47 | 320.308 | 379.88 |
| Accumulated Depreciation, Total | -106.539 | -115.65 | -133.673 | -163.718 | -185.043 | -180.325 |
| Goodwill, Net | 164.578 | 174.313 | 185.638 | 338.094 | 326.51 | 328.714 |
| Intangibles, Net | 53.746 | 68.491 | 74.087 | 144.336 | 145.221 | 153.698 |
| Long Term Investments | 0.124 | 19.3 | 0.122 | 5.173 | 4.108 | 6.713 |
| Note Receivable - Long Term | 13.445 | 14.565 | 9.29 | 10.961 | 9.225 | 9.191 |
| Other Long Term Assets, Total | 93.865 | 79.855 | 79.227 | 102.484 | 104.014 | 94.079 |
| Total Current Liabilities | 285.897 | 316.078 | 280.18 | 339.6 | 297.584 | 448.118 |
| Accounts Payable | 86.531 | 100.463 | 101.437 | 118.12 | 91.679 | 145.465 |
| Accrued Expenses | 79.908 | 80.259 | 98.181 | 115.657 | 109.294 | 137.816 |
| Notes Payable/Short Term Debt | 22.72 | 5.733 | 15.71 | 0.192 | 0.209 | 0.645 |
| Current Port. of LT Debt/Capital Leases | 2.854 | 2.819 | 3.529 | 14.661 | 15.512 | 19.341 |
| Other Current Liabilities, Total | 93.884 | 126.804 | 61.323 | 90.97 | 80.89 | 144.851 |
| Total Liabilities | 449.893 | 407.731 | 368.588 | 623.69 | 583.133 | 736.641 |
| Total Long Term Debt | 7.736 | 3.588 | 7.321 | 151.837 | 140.636 | 178.425 |
| Long Term Debt | 1.61 | 0.593 | 0 | 109.009 | 87.543 | 76.496 |
| Capital Lease Obligations | 6.126 | 2.995 | 7.321 | 42.828 | 53.093 | 101.929 |
| Deferred Income Tax | 10.397 | 8.918 | 5.234 | 18.198 | 17.166 | 15.438 |
| Minority Interest | 53.326 | 26.358 | 21.17 | 18.517 | 18.841 | 18.056 |
| Other Liabilities, Total | 92.537 | 52.789 | 54.683 | 95.538 | 108.906 | 76.604 |
| Total Equity | 797.837 | 1215.38 | 1293.46 | 1398.44 | 1431.72 | 1659.33 |
| Common Stock | 81.31 | 89.441 | 89.441 | 89.441 | 89.441 | 89.441 |
| Additional Paid-In Capital | 313.863 | 620.137 | 620.137 | 620.137 | 620.137 | 620.137 |
| Retained Earnings (Accumulated Deficit) | 458.335 | 555.215 | 632.486 | 744.673 | 808.922 | 1000.48 |
| Other Equity, Total | -55.671 | -49.416 | -48.6 | -55.812 | -86.783 | -50.729 |
| Total Liabilities & Shareholders’ Equity | 1247.73 | 1623.11 | 1662.05 | 2022.13 | 2014.85 | 2395.97 |
| Total Common Shares Outstanding | 81.3096 | 89.4406 | 89.4406 | 89.4406 | 89.4406 | 89.4406 |
| Īstermiņa Ieguldījumi | 4.39 | 1.165 | 0 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Apgrozāmo Līdzekļu Kopsumma | 1451.74 | 1604.02 | 1674.57 | ||
| Nauda un Īstermiņa Ieguldījumi | 17.352 | 17.918 | 21.589 | ||
| Nauda un Ekvivalenti | 8.315 | 7.439 | 8.401 | ||
| Īstermiņa Ieguldījumi | 9.037 | 10.479 | 13.188 | ||
| Debitoru Parādu Kopsumma, Neto | 1140.1 | 1274.3 | 1298.01 | ||
| Accounts Receivable - Trade, Net | 164.928 | 185.94 | 156.475 | ||
| Total Inventory | 274.078 | 286.375 | 328.867 | ||
| Other Current Assets, Total | 20.211 | 25.422 | 26.105 | ||
| Total Assets | 2217.7 | 2395.97 | 2526.01 | ||
| Property/Plant/Equipment, Total - Net | 189.302 | 199.555 | 205.703 | ||
| Goodwill, Net | 323.349 | 328.714 | 379.934 | ||
| Intangibles, Net | 144.045 | 153.698 | 163.484 | ||
| Long Term Investments | 4.843 | 6.713 | 6.843 | ||
| Note Receivable - Long Term | 8.339 | 9.191 | 9.096 | ||
| Other Long Term Assets, Total | 96.077 | 94.079 | 86.374 | ||
| Total Current Liabilities | 347.866 | 448.118 | 499.258 | ||
| Accounts Payable | 123.336 | 145.465 | 140.474 | ||
| Accrued Expenses | 92.307 | 127.787 | 109.277 | ||
| Notes Payable/Short Term Debt | 0 | 0 | 0 | ||
| Current Port. of LT Debt/Capital Leases | 17.876 | 19.341 | 18.97 | ||
| Other Current Liabilities, Total | 114.347 | 155.525 | 230.537 | ||
| Total Liabilities | 672.152 | 736.641 | 788.612 | ||
| Total Long Term Debt | 192.216 | 178.425 | 189.666 | ||
| Long Term Debt | 90.194 | 76.496 | 88.588 | ||
| Capital Lease Obligations | 102.022 | 101.929 | 101.078 | ||
| Deferred Income Tax | 16.932 | 15.438 | 15.035 | ||
| Minority Interest | 17.705 | 18.056 | 18.693 | ||
| Other Liabilities, Total | 97.433 | 76.604 | 65.96 | ||
| Total Equity | 1545.55 | 1659.33 | 1737.39 | ||
| Common Stock | 89.441 | 89.441 | 89.441 | ||
| Additional Paid-In Capital | 620.137 | 620.137 | 620.137 | ||
| Retained Earnings (Accumulated Deficit) | 909.534 | 1000.48 | 1048.65 | ||
| Other Equity, Total | -73.565 | -50.729 | -20.833 | ||
| Total Liabilities & Shareholders’ Equity | 2217.7 | 2395.97 | 2526.01 | ||
| Total Common Shares Outstanding | 89.4406 | 89.4406 | 89.4406 |
- Ikgadējs
- Ceturkšņa
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Neto ienākumi/Sākuma Līnija | 99.97 | 135.778 | 126.23 | 160.579 | 123.421 | 237.519 |
| Nauda no Darbības | 111.77 | 37.732 | 187.207 | 219.634 | 178.527 | 362.663 |
| Nauda no Darbības | 20.226 | 24.235 | 31.282 | 48.37 | 60.425 | 61.584 |
| Bezskaidras Naudas Preces | 80.32 | 47.269 | 54.526 | 76.373 | 58.691 | 110.074 |
| Cash Taxes Paid | 43.792 | 54.73 | 48.364 | 65.07 | 58.964 | 97.908 |
| Samaksātie Procenti Naudā | 1.565 | 1.559 | 1.94 | 1.903 | 1.365 | 1.629 |
| Izmaiņas Apgrozāmajā Kapitālā | -88.746 | -169.55 | -24.831 | -65.688 | -64.01 | -46.514 |
| Nauda no Ieguldījumu Darbībām | 77.332 | -55.931 | -28.874 | -145.846 | -70.947 | -75.2 |
| Kapitālie Izdevumi | -27.917 | -39.022 | -34.756 | -46.711 | -44.986 | -66.101 |
| Citi Ieguldījumu Naudas Plūsmas Posteņi, Kopā | 105.249 | -16.909 | 5.882 | -99.135 | -25.961 | -9.099 |
| Nauda no Darbībām ar Finansēšanu | -195.021 | 14.494 | -157.237 | -58.637 | -122.961 | -285.889 |
| Naudas Plūsma Finansēšanas Posteņos | -160.888 | -259.854 | -104.529 | 4.321 | -48.775 | -223.862 |
| Total Cash Dividends Paid | -30.898 | -37.565 | -49.192 | -49.192 | -58.136 | -44.72 |
| Parādu Izsniegšana (Atkāpšanās), Neto | -3.235 | -3.123 | -3.516 | -13.766 | -16.05 | -17.307 |
| Ārvalstu Valūtas Ietekme | 1.588 | -1.08 | 1.657 | 0.81 | -1.056 | -0.337 |
| Neto Izmaiņas Naudā | -4.331 | -4.785 | 2.753 | 15.961 | -16.437 | 1.237 |
| Akciju Izsniegšana (Atkāpšanās), Neto | 315.036 | 0 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 101.501 | 130.104 | |||
| Cash From Operating Activities | 151.878 | 74.484 | |||
| Cash From Operating Activities | 29.924 | 33.045 | |||
| Non-Cash Items | 44.673 | 16.671 | |||
| Cash Taxes Paid | 41.015 | 61.722 | |||
| Cash Interest Paid | 0.67 | 0.679 | |||
| Changes in Working Capital | -24.22 | -105.336 | |||
| Cash From Investing Activities | -28.769 | -54.311 | |||
| Capital Expenditures | -23.26 | -35.335 | |||
| Other Investing Cash Flow Items, Total | -5.509 | -18.976 | |||
| Cash From Financing Activities | -124.663 | -18.33 | |||
| Financing Cash Flow Items | -116.396 | -9.441 | |||
| Issuance (Retirement) of Debt, Net | -8.267 | -8.889 | |||
| Foreign Exchange Effects | -0.31 | -0.881 | |||
| Net Change in Cash | 2.113 | 0.962 |
| Investora vārds | Investora veids | Nenokārtots procents | Akcijas turējumā | Izmaiņas akcijās | Turēšanas termiņš | Apgrozījuma reitings |
|---|---|---|---|---|---|---|
| Carl Zeiss Group | Corporation | 59.14 | 52895153 | 35776 | 2022-11-15 | |
| Capital Research Global Investors | Investment Advisor | 5.0436 | 4511021 | 0 | 2022-11-15 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 1.1497 | 1028301 | 4437 | 2022-12-31 | LOW |
| Groupama Asset Management | Investment Advisor | 0.9086 | 812662 | -153363 | 2022-06-30 | LOW |
| Invesco Advisers, Inc. | Investment Advisor | 0.9057 | 810045 | -54793 | 2022-12-31 | LOW |
| DWS Investment GmbH | Investment Advisor/Hedge Fund | 0.7939 | 710061 | 40772 | 2022-12-31 | LOW |
| BlackRock Asset Management Deutschland AG | Investment Advisor | 0.7694 | 688162 | 20015 | 2022-12-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.751 | 671724 | 10814 | 2023-01-31 | LOW |
| Allianz Global Investors GmbH | Investment Advisor | 0.704 | 629647 | -2942 | 2022-12-31 | LOW |
| Capital World Investors | Investment Advisor | 0.6749 | 603665 | 0 | 2022-12-31 | LOW |
| Candriam Luxembourg S.A. | Investment Advisor | 0.6012 | 537718 | 2298 | 2022-12-31 | HIGH |
| Amundi Asset Management, SAS | Investment Advisor/Hedge Fund | 0.5549 | 496342 | 96816 | 2022-12-31 | HIGH |
| La Financière de l'Echiquier | Investment Advisor | 0.5405 | 483394 | -6 | 2022-11-30 | MED |
| Oddo BHF Asset Management S.A.S | Investment Advisor/Hedge Fund | 0.4811 | 430328 | -12380 | 2022-12-31 | LOW |
| BlackRock Advisors (UK) Limited | Investment Advisor/Hedge Fund | 0.4178 | 373691 | -1121 | 2022-12-31 | LOW |
| Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 0.4095 | 366292 | -451602 | 2022-12-31 | LOW |
| Deka Investment GmbH | Investment Advisor/Hedge Fund | 0.3397 | 303842 | -13379 | 2022-12-31 | LOW |
| Columbia Threadneedle Investments (UK) | Investment Advisor/Hedge Fund | 0.25 | 223624 | -542 | 2022-10-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.2344 | 209658 | -4301 | 2022-12-31 | LOW |
| BNP Paribas Asset Management France SAS | Investment Advisor/Hedge Fund | 0.2275 | 203480 | -35852 | 2022-12-31 | LOW |
Kāpēc izvēlēties Capital.com? Mūsu skaitļi runā paši par sevi.
Capital.com Group +500000+
Tirgotāji
93000+
Ikmēneša aktīvie klienti
$57000000+
Ikmēneša ieguldījumu apjoms
$31000000+
Izmēģināt tagad Izņemts katru mēnesi
Treidinga kalkulators
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Tirdzniecības komisija
0
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
Finanšu svira
20:1
- 20
- 100
- 500
- 1000
- 10000
Investīcija
Darījuma apjoms (Kredītplecs x Investīcija):
Atvēršana
Aizvēršana
Īss Garšs
Carl Zeiss Meditec Company profile
Par Carl Zeiss Meditec AG
Carl Zeiss Meditec AG ir Vācijā bāzēts medicīnas tehnoloģiju un ierīču uzņēmums. Tas piedāvā pilnīgus risinājumus optisku slimību diagnostikai un ārstēšanai, vizualizācijas risinājumus mikroķirurģijai un citas tehnoloģijas, piemēram, intraoperatīvo staru terapiju. Uzņēmums darbojas divos segmentos: Oftalmoloģijas ierīces un mikroķirurģija. Oftalmoloģisko ierīču segmentā ietilpst darbības oftalmoloģijas jomā, piemēram, intraokulārās lēcas, ķirurģiskās vizualizācijas risinājumi un medicīnas lāzeru un diagnostikas sistēmas. Mikroķirurģijas segmentā ietilpst darbības neiroķirurģijas, ausu, deguna un rīkles ķirurģijas jomā, kā arī darbības intraoperatīvā starojuma jomā. Uzņēmumam ir vairākas ražotnes Eiropā, Amerikas Savienotajās Valstīs un Āzijā.
| Industry: | Advanced Medical Equipment & Technology (NEC) |
Göschwitzer Straße 51-52
JENA
THUERINGEN 07745
DE
Peļņas Atskaite
- Annual
- Quarterly
Cilvēki arī skatās
Vai joprojām meklējat mākleri, kuram varat uzticēties?
Pievienojieties 500 000+ tirgotājiem visā pasaulē, kuri izvēlējās tirgoties ar Capital.com